In this study, we found that autoantibodies in patients with Graves’ disease preferentially recognize thyroid-stimulating hormone receptor (TSHR) complexed with MHC class II molecules of Graves’ disease risk alleles, suggesting that the aberrant TSHR transported by MHC class II molecules is the target of autoantibodies produced in Graves’ disease. Here, HLA-C is linked to Graves disease.